Product Overview

Vildalip Met 50/1000 is a dual-action oral antidiabetic formulation containing Vildagliptin IP 50 mg and Metformin Hydrochloride IP 1000 mg, developed for the effective management of Type 2 Diabetes Mellitus. This combination therapy brings together the benefits of a DPP-4 inhibitor and a biguanide to provide comprehensive blood glucose control through complementary mechanisms of action.

Vildagliptin enhances the body’s natural incretin system by increasing glucose-dependent insulin secretion and reducing glucagon release, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity. Together, these mechanisms help achieve effective control of both fasting and postprandial blood glucose levels while supporting long-term metabolic health.

Vildalip Met 50/1000 is commonly prescribed for patients whose blood glucose levels are not adequately controlled with lifestyle modifications or monotherapy. It may be used as part of a comprehensive diabetes management plan that includes a balanced diet, regular physical activity, and routine blood glucose monitoring. The combination therapy reduces pill burden, improves treatment adherence, and offers a convenient approach to long-term diabetes care.

Manufactured under stringent pharmaceutical quality standards, Vildalip Met 50/1000 delivers consistent efficacy, safety, and reliability, making it a trusted therapeutic option for healthcare professionals managing Type 2 Diabetes Mellitus.

How It Works

Vildagliptin inhibits the DPP-4 enzyme, increasing the levels of incretin hormones that stimulate glucose-dependent insulin secretion and suppress glucagon release. Metformin Hydrochloride reduces glucose production in the liver, decreases intestinal glucose absorption, and improves the body’s sensitivity to insulin. Together, these complementary mechanisms help maintain stable blood glucose levels and support effective long-term glycemic control.

Therapeutic Applications

Vildalip Met 50/1000 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Inadequately Controlled Blood Glucose Levels
• Long-Term Glycemic Management
• Combination Antidiabetic Therapy
• Patients requiring dual-mechanism glucose control

Key Benefits

• Dual-action therapy for comprehensive blood glucose management.
• Combines Vildagliptin and Metformin in a single tablet.
• Helps control both fasting and postprandial blood glucose levels.
• Improves insulin secretion and insulin sensitivity.
• Reduces pill burden and supports better treatment adherence.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Vildalip Met 50/1000 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Vildalip Met 50/1000 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.